Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Dynamics Research

Executive Summary: Mdivi-1 is a cell-permeable, selective DRP1 inhibitor that blocks mitochondrial fission in yeast and mammalian cells, supporting mitochondrial dynamics research (APExBIO). It suppresses Bid-activated Bax/Bak-dependent cytochrome c release, a key step in intrinsic apoptosis (Li et al. 2025). In vitro, Mdivi-1 at 50 μM inhibits DRP1 self-assembly and attenuates apoptosis, as verified by reduced annexin V staining. In vivo, 50 mg/kg intraperitoneal Mdivi-1 increases retinal ganglion cell survival and reduces GFAP expression following ischemic injury in mice, without detectable effects on systemic physiology. Mdivi-1's solubility, storage, and workflow parameters make it an accessible tool for apoptosis assays and mitochondrial disease modeling (APExBIO).

Biological Rationale

Mitochondrial fission and fusion are core processes regulating mitochondrial morphology, bioenergetics, and cell fate. The large GTPase DRP1 (dynamin-related protein 1) catalyzes mitochondrial division, influencing apoptosis and disease progression (Li et al. 2025). Dysregulated mitochondrial dynamics are implicated in neurodegeneration, ischemic injury, and vascular remodeling. Targeted inhibition of DRP1-mediated fission via small molecules such as Mdivi-1 enables mechanistic studies and model interventions (see also—this article extends prior coverage by integrating recent in vivo neuroprotection data).

Mechanism of Action of Mdivi-1

Mdivi-1 is a selective, reversible inhibitor of DRP1 and Dnm1 GTPase activity. It prevents DRP1 oligomerization and mitochondrial outer membrane scission, blocking mitochondrial fission events. At 50 μM in vitro, Mdivi-1 inhibits DRP1 self-assembly and GTP hydrolysis, resulting in reduced mitochondrial fragmentation. Mechanistically, Mdivi-1 blocks Bid-activated Bax/Bak-dependent cytochrome c release, attenuating mitochondrial outer membrane permeabilization and downstream caspase-independent apoptosis (Li et al. 2025). This precise modulation distinguishes it from non-selective GTPase inhibitors.

Evidence & Benchmarks

• Mdivi-1 at 50 μM inhibits DRP1 self-assembly and mitochondrial division in vitro, reducing mitochondrial fragmentation in yeast and mammalian cells (APExBIO).
• Mdivi-1 potently blocks Bid-activated Bax/Bak-dependent cytochrome c release from mitochondria, preventing apoptosis-associated mitochondrial outer membrane permeabilization (Li et al. 2025).
• 50 mg/kg intraperitoneal administration in C57BL/6 mice increases retinal ganglion cell survival and decreases GFAP protein expression after ischemic injury, confirming in vivo neuroprotection (APExBIO).
• Mdivi-1 application does not significantly alter blood pressure or overt behavior in treated animals (APExBIO).
• In SMCs exposed to conditioned medium from ADAM10-overexpressing ECs, addition of Mdivi-1 reduces proliferation and increases apoptosis, implicating DRP1 in pathologic vascular remodeling (Li et al. 2025).

Applications, Limits & Misconceptions

Mdivi-1 is validated for:

• Apoptosis assays in mammalian and yeast cells.
• Mitochondrial dynamics research, including assays for fission/fusion balance.
• Neuroprotection studies in ischemic retina and other CNS models (see related—this article provides updated in vivo neuroprotection benchmarks vs. prior workflow guides).
• Vascular remodeling and cell proliferation/apoptosis models, particularly under hypoxic stress (see also—we extend the mechanistic focus to multi-pathway crosstalk).

Common Pitfalls or Misconceptions

• Mdivi-1 is not a pan-dynamin inhibitor: It does not broadly inhibit all dynamin family GTPases; selectivity is for DRP1/Dnm1.
• Solubility limitations: Mdivi-1 is insoluble in water and ethanol; must be dissolved in DMSO (≥17.65 mg/mL) and pre-warmed or sonicated for best results.
• Not suitable for long-term solution storage: Mdivi-1 solutions degrade over time; solid material should be stored at -20°C and solutions at < -20°C for limited months.
• Not a universal apoptosis blocker: Mdivi-1's effects are context-dependent and may not prevent apoptosis in DRP1-independent models.
• Does not affect systemic physiological parameters at neuroprotective doses: Blood pressure and behavior remain unchanged in mice treated with 50 mg/kg i.p. Mdivi-1.

Workflow Integration & Parameters

For in vitro studies, Mdivi-1 is typically used at 50 μM, dissolved in DMSO. For in vivo neuroprotection, 50 mg/kg intraperitoneal dosing in C57BL/6 mice is reported. Stock solutions (≥17.65 mg/mL in DMSO) are best stored in aliquots at < -20°C. Warm to 37°C or use an ultrasonic bath to facilitate dissolution. Avoid repeated freeze-thaw cycles. Mdivi-1 (SKU A4472) can be sourced from APExBIO, the validated supplier.

Conclusion & Outlook

Mdivi-1 is a rigorously characterized, selective DRP1 inhibitor that enables precise modulation of mitochondrial fission and apoptosis in research settings. Its use clarifies the role of DRP1 in mitochondrial dynamics, neuroprotection, and vascular remodeling, offering translational insight into disease modeling. Further studies may delineate its utility in complex, multi-pathway contexts and identify new therapeutic opportunities (Li et al. 2025).